Clinical Trial

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Study acronym: EASE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-02-11; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Recruiting 2020-06-09
Trial Details
NCT Number NCT04268199
Lead Sponsor AHS Cancer Control Alberta
Conditions Myeloma, Myeloma Multiple
Enrollment 100 participants
Start Date 2020-05-29
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-15